TelyRx Finco Inc. filed a Form D with the Securities and Exchange Commission on 2026-04-20.
TelyRx Finco Inc. filed a Form D notice of an exempt securities offering with the SEC on April 20, 2026. The filing reports $12.62M sold. Its industry group is Pharmaceuticals. It names Vanessa Slowey (Director, Executive Officer), John Cascio (Executive Officer, Director) (SEC Form D, April 20, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like TelyRx Finco Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-04-20 · the record
Pitching, partnering or investing alongside them? See who really runs and owns TelyRx Finco Inc.
Free to see. No signup.
More on the people and the money behind TelyRx Finco Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when TelyRx Finco Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when TelyRx Finco Inc. raises, hires or launches. No email unless you switch it on.
Watch TelyRx Finco Inc. →Get the full cited report on TelyRx Finco Inc.
What the filing shows about TelyRx Finco Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on TelyRx Finco Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives TelyRx Finco Inc.'s address as 333 Bay Street, Suite 2400, Toronto, A6 M5H 2T6.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
TelyRx Finco Inc. is a registered filer with the SEC (CIK 2125491) and has filed since 2026-04-20. 1 filing is on record, the latest on 2026-04-20.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
TelyRx Finco Inc.'s Form D of 2026-04-20 names Vanessa Slowey and John Cascio as its officers, directors or promoters.
Its new offerings report $12.62M sold across 1 offering, as its own filings state.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week. The dot is this raise, $12.62M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Vanessa Slowey is named as Director and Executive Officer on the Form D that TelyRx Finco Inc. filed with the SEC on 20 April 2026, one of 2 people that filing names.
John Cascio is named as Executive Officer and Director on the Form D that TelyRx Finco Inc. filed with the SEC on 20 April 2026, one of 2 people that filing names.
2 people named on the filing — 2 holding an executive role.
Named as of the 2026-04-20 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about TelyRx Finco Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on TelyRx Finco Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TelyRx Finco Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist TelyRx Finco Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind TelyRx Finco Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for TelyRx Finco Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/telyrx-finco-inc-form-d-26000629